论文部分内容阅读
目的:研究结肠癌患者外周血中单核细胞趋化蛋白1(MCP-1)水平的变化,探讨其临床意义。方法:采用酶联免疫吸附法(ELISA)分别测定98例结肠癌患者(37例未发生肝转移61例发生肝转移)和40例正常人(对照组)血清MCP-1的水平,并进行比较。结果:发生肝转移结肠癌患者血清MCP-1水平为(158.7±267.4)pg/ml,未发生肝转移结肠癌患者血清MCP-1水平为(78.3±116.1)pg/ml,正常对照组血清MCP-1水平为(57.1±48.8)pg/ml。临床相关性发现血清MCP-1水平与肝转移、临床分期相关。结论:MCP-1在结肠癌肝转移中起重要作用,监测血清MCP-1水平可反映结肠癌的进展程度,具有重要的临床价值。
Objective: To study the changes of monocyte chemoattractant protein-1 (MCP-1) in peripheral blood of patients with colon cancer and to explore its clinical significance. Methods: The serum levels of MCP-1 in 98 patients with colon cancer (37 without hepatic metastasis and 61 with liver metastasis) and 40 normal controls (control group) were determined by enzyme-linked immunosorbent assay (ELISA) Compare. Results: The serum levels of MCP-1 in the patients with liver metastasis and colon cancer were (158.7 ± 267.4) pg / ml, those without liver metastasis and colon cancer were (78.3 ± 116.1) pg / ml, -1 level was (57.1 ± 48.8) pg / ml. Clinical correlation found serum MCP-1 levels and liver metastasis, clinical stage related. Conclusions: MCP-1 plays an important role in hepatic metastasis of colon cancer. Monitoring MCP-1 level may reflect the progression of colon cancer and has important clinical value.